MRD Tied to Allo-Transplant Benefit in NPM1-Mutated Acute Myeloid Leukemia
SAN DIEGO — Measurable residual disease (MRD) after induction therapy can guide the use of allogeneic transplant in patients with NPM1-mutated acute myeloid leukemia (AML) in first remission, regardless of whether FLT3 internal tandem duplication (ITD) mutations are present as well, according to an analysis of two randomized trials. Of more than 700 patients in […]
Clinical Challenges: Sequencing in Metastatic TNBC
As new treatment options continue to emerge for triple-negative breast cancer (TNBC), sequencing of therapy promises to get ever more complicated. TNBC had been estimated to account for about 15% of all breast cancer diagnoses, but that proportion shrank with the new HER2-low designation, which accounts for approximately one-third of patients diagnosed with TNBC. An […]
Higher-Dose Fluvoxamine Fails for COVID Outpatients
The extensive quest to repurpose a cheap therapy for non-hospitalized COVID patients has once again fallen short, this time using a higher dose of fluvoxamine (Luvox), a selective serotonin reuptake inhibitor (SSRI). In the latest readout from the multi-platform ACTIV-6 trial, time to sustained recovery landed at an identical 10 days whether patients with mild […]
‘We’re Not There Yet’: CAR T-Cell Therapy for Renal Cell Carcinoma
NASHVILLE, Tenn. — Chimeric antigen receptor (CAR) T-cell therapy has the potential to become standard-of-care therapy for renal cell carcinoma (RCC) that does not respond to current therapies, an RCC specialist said here. CAR T-cell therapy is not yet ready for clinical practice, but enrolling patients in the growing number of clinical trials can help […]
Maintenance Selinexor May Boost PFS in TP53 Wild-Type Advanced Endometrial Cancer
SEOUL, South Korea — Maintenance therapy with selinexor (Xpovio) seemed to substantially extend progression-free survival (PFS) in patients with wild-type TP53 advanced or recurrent endometrial cancer, according to data from the SIENDO trial. The updated, long-term data from the phase III study showed that, at a median follow-up of 25.3 months, median PFS was 27.4 […]
Clinical Challenges: Test Your Knowledge of HIV
A MedPage Today Clinical Challenges series on HIV looked at long-acting antiretroviral therapy (ART), HIV care during the COVID pandemic, and efforts to destigmatize HIV pre-exposure prophylaxis (PrEP). The following is a three-question quiz to test your knowledge on each aspect of the series. Correct answers and explanations appear after completing the quiz. Please enable […]
Tebentafusp’s OS Benefit in Uveal Melanoma Holds Up at 3 Years
MADRID — The significant survival benefit with the bispecific T-cell receptor therapy tebentafusp (Kimmtrak) held up at 3 years for selected patients with previously untreated metastatic uveal melanoma, updated results of a phase III trial demonstrated. In HLA-A*02:01-positive patients, landmark analyses showed improved overall survival (OS) at 1, 2, and 3 years with tebentafusp versus […]
SBRT Noninferior to Conventional RT for Intermediate-Risk Prostate Cancer
SAN DIEGO — Stereotactic body radiation therapy (SBRT) was as effective as conventional radiation therapy (CRT) in treating intermediate-risk prostate cancer, according to results from the randomized PACE-B trial. Among 874 patients, those randomized to CRT had a biochemical/clinical failure-free rate of 94.6% versus 95.8% for those randomized to SBRT (HR 0.73, 90% CI 0.47-1.12, […]
Hypofractionated RT for Breast Cancer Post-Mastectomy as Effective as Standard RT
SAN DIEGO — Hypofractionated radiation appeared to be as safe and effective as conventionally fractionated radiation therapy for patients with breast cancer who underwent implant-based breast reconstruction following mastectomy, according to results from the FABREC randomized trial. For the study’s primary outcome of change in physical well-being score, patients in both groups reported similar scores […]
SBRT Added to Standard Tx Boosts Outcomes in Oligometastatic Prostate Cancer
Combining stereotactic body radiation therapy (SBRT) with standard systemic therapy yielded significant increases in the rates of biochemical response and progression-free survival (PFS) in patients with oligometastatic castrate-resistant prostate cancer (CRPC), the phase II randomized ARTO trial showed. In a cohort of 157 patients at 6 months after the start of treatment, biochemical response was […]